Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
NTLA/Financials
Segments · Problems · Premarket · Compliance
Segment Analysis
Segments · Problems · Premarket · ComplianceSegment Analysis
Revenue · By Business Segment
These hierarchically ordered segment trees are sourced from the most recent 10-K filings, directly from the SEC.
Not available for NTLA
Revenue · By Area
This map and table comes from the most recent 10-K filings, directly from the SEC.
Not available for NTLA